Pfizer cleared the next hurdle in the race to get its Covid-19 vaccine approved for emergency use in the U.S. after the Food and Drug Administration on Tuesday released documents that did not raise any new issues about its safety or efficacy.

The analysis, conducted by FDA staff, affirmed that the coronavirus vaccine, developed by Pfizer and its German partner BioNTech, was 95% effective in preventing Covid-19 after two doses.